Molly Henderson - Jun 2, 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Signature
/s/ Larry Miller, Attorney-in-Fact for Molly Henderson
Stock symbol
PHAT
Transactions as of
Jun 2, 2023
Transactions value $
-$22,368
Form type
4
Date filed
6/5/2023, 06:32 PM
Previous filing
May 23, 2023
Next filing
Jul 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Sale -$22.4K -1.96K -2.78% $11.41 68.5K Jun 2, 2023 Direct F1, F2, F3
holding PHAT Common Stock 339 Jun 2, 2023 By 401(K)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022.
F2 Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices 11.41 and 11.5653. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.